Pfizer to assess Akili game as Alzheimer's biomarker

Pfizer is launching a clinical study to assess the potential of Akili Interactive Labs’ Project EVO gaming platform as a biomarker or cognitive endpoint for people at risk of Alzheimer’s disease.

Akili is a US-based company developing mobile video games as potential therapeutics for neurological disorders or as tools for remote monitoring of core cognition.

The Akili platform is designed to quantify and improve the ability of individuals to deal with cognitive interference affecting their ability to pay attention, plan or make decisions. These deficits are common symptoms of a number of degenerative diseases such as Alzheimer’s, as well as psychiatric conditions like attention deficit hyperactivity disorder (ADHD), autism and depression.